.jpg)
STAT+: Siddhartha Mukherjee forms his second biotech company, focused on using cell therapy for solid tumors
Almost five years after debuting his first biotech company, noted writer and oncologist Siddhartha Mukherjee has officially unveiled his second: Myeloid Therapeutics. The new company, based in Cambridge, Mass., launched Wednesday with a $50 million Series A.
Myeloid is putting a twist on cell cancer therapies like CAR-T that are already successful in blood cancers and using a similar idea to take on conditions like glioblastoma, which form solid tumors. It will use so-called myeloid cells, the collective term for some kinds of blood and immune cells, to trigger the rest of a person’s immune system.
